SEC charges former NBTY counsel
This article was originally published in The Tan Sheet
The U.S. Securities & Exchange Commission filed insider trading charges against former NBTY associate general counsel Mitchell Drucker and his father Ronald Drucker March 2, the commission announces. According to the complaint filed in federal court for the southern district of New York, Mitchell Drucker sold of all his NBTY stock on Oct. 18, 2001 after learning that the firm's fourth-quarter earnings would be 50% lower than analysts had previously predicted. The information was not publicly released until the following day. Mitchell Drucker also instructed his father to sell his shares and oversaw the sale of all of a friend's shares in the firm. Mitchell and Ronald Drucker avoided losses of $138,174 and $51,116, respectively. In addition to the disgorgement of losses avoided and civil penalties, SEC also is asking that the court bar Mitchell Drucker from acting as an officer or director of a public company...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.